Navigation Links
Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
Date:11/9/2010

for at least 5 and 28 days, respectively, prior to first study drug infusion. Primary endpoint was responder rate on a combined index of clinical disease activity at week 12 (defined as reduction of all baseline (BL) BILAG 2004 A to B/C/D and BL BILAG B to C/D, no BILAG worsening in other organ systems, and no deterioration in SLEDAI or physician global assessment [VAS]), with no CS, IS and antimalarials increase over BL dose. The study was not powered to detect statistical differences between treatment arms.

By week 12 (see table) combined responder index rates were higher in all epratuzumab groups than in the placebo group, reaching statistical significance in the epratuzumab 600mg weekly group (2400mg cumulative) and the combined group of all 74 patients who received a cumulative dose of 2400mg (600mg weekly and 1200mg every other week).Dose regimenPBO
(n=38)Emab cd
200mgEmab cd
800mgEmab cd 2400mgEmab cd
3600mg100mg
EOW
(n=39)400mg
EOW
(n=38)600mg
weekly
(n=37(a))1200mg
EOW
(n=37)Combined
group
(n=74)1800mg
EOW
(n=38)Responders n (%)

8 (21.1)

12 (30.8)

10 (26.3)

17 (45.9)

15 (40.5)

32 (43.2)

9 (23.7)Odds ratio1.7

(0.6-4.7)

1.3

(0.5-3.9)

3.2

(1.1-8.8)

P=0.03(b)

2.6

(0.9-7.1)

P=0.07 (b)

2.9

(1.2-7.1) p=0.02 (b)

1.2

(0.4-3.4)Table - Combined responder index, week 12 (ITT population)Emab = epratuzumab

(a) 2 patients randomized but never received drug

(b) p values not adjusted for multiple comparisonsAdditionally, by Week 12, more patients in the epratuzumab 600mg weekly group, compared with placebo, had an improvement from BILAG A/B to BILAG D in the 6 body systems, indicating no
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... April 6 (HealthDay News) -- Compared with normal weight ... and infections during and after a hysterectomy, a new ... 20,353 women who had a hysterectomy to treat non-cancerous ... tumors and pain. Women with a body-mass index ...
... able to predict which adults with mild cognitive impairment are ... results of a study published online and in the June ... is an intermediate stage between the decline in mental abilities ... associated with dementia, a group of brain disorders that includes ...
... national prescribing patterns shows that more than half of ... filled another opioid prescription within the previous 30 days. ... at reducing abuse of prescription opioids. Researchers from ... of the National Institutes of Health, will publish results ...
... , TUESDAY, April 5 (HealthDay News) -- For people ... promise, researchers report. The device, surgically placed just ... jolt to the carotid arteries. This is said to ... activation therapy. The researchers were scheduled to present ...
... persistence and recurrence of H5N1 avian influenza in endemic regions ... birds. Trade in poultry, poultry products and caged birds, and ... these areas. Several recent outbreaks of avian influenza have suggested ... the virus over long distances. In a paper ...
... April 5 (HealthDay News) -- The substantial increase in ... emergency departments between 1995 and 2008 highlights the need ... researchers. They analyzed National Hospital Ambulatory Medical Care ... rose from about 330,000 in 1995 to 1.65 million ...
Cached Medicine News:Health News:Weight Linked to Complications in Some Hysterectomy Patients 2Health News:Using MRI, researchers may predict which adults will develop Alzheimer's 2Health News:Analysis of opioid prescription practices finds areas of concern 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 3Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:As CT Scans of Kids Soar, Experts Urge Oversight 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Sterile perfluorocarbon for intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Round knurled handle. Overall length 130 mm....
Medicine Products: